Income Statement NovoCure Limited
Equities
NVCR
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.42 USD | -3.51% |
|
-7.70% | -10.15% |
Dec. 02 | HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating | MT |
Dec. 02 | NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 351M | 494M | 535M | 538M | 509M | |||||
Total Revenues | 351M | 494M | 535M | 538M | 509M | |||||
Cost of Goods Sold, Total | 88.28M | 106M | 114M | 114M | 128M | |||||
Gross Profit | 263M | 388M | 421M | 424M | 382M | |||||
Selling General & Admin Expenses, Total | 185M | 225M | 263M | 306M | 387M | |||||
R&D Expenses | 79M | 132M | 201M | 206M | 221M | |||||
Other Operating Expenses, Total | 264M | 357M | 464M | 512M | 608M | |||||
Operating Income | -587K | 30.81M | -43.69M | -88.91M | -226M | |||||
Interest Expense, Total | -13.87M | -17.66M | -3.44M | -3.33M | -3.32M | |||||
Interest And Investment Income | 4.4M | 1.79M | 791K | 10.96M | 19.64M | |||||
Net Interest Expenses | -9.47M | -15.87M | -2.65M | 7.63M | 16.32M | |||||
Currency Exchange Gains (Loss) | -431K | 2.65M | -4.03M | -3.52M | -797K | |||||
Other Non Operating Income (Expenses) | -338K | -389K | -1.37M | -1.26M | -790K | |||||
EBT, Excl. Unusual Items | -10.83M | 17.2M | -51.74M | -86.06M | -211M | |||||
Restructuring Charges | - | - | - | - | -6.23M | |||||
Gain (Loss) On Sale Of Investments | 2.33M | 1.32M | 306K | 4.83M | 26.4M | |||||
Asset Writedown | -327K | -409K | -639K | -611K | -483K | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -8.82M | 18.1M | -52.08M | -81.85M | -192M | |||||
Income Tax Expense | -1.59M | -1.71M | 6.28M | 10.69M | 15.3M | |||||
Earnings From Continuing Operations | -7.23M | 19.81M | -58.35M | -92.53M | -207M | |||||
Net Income to Company | -7.23M | 19.81M | -58.35M | -92.53M | -207M | |||||
Net Income - (IS) | -7.23M | 19.81M | -58.35M | -92.53M | -207M | |||||
Net Income to Common Incl Extra Items | -7.23M | 19.81M | -58.35M | -92.53M | -207M | |||||
Net Income to Common Excl. Extra Items | -7.23M | 19.81M | -58.35M | -92.53M | -207M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.07 | 0.2 | -0.56 | -0.88 | -1.95 | |||||
Basic EPS - Continuing Operations | -0.07 | 0.2 | -0.56 | -0.88 | -1.95 | |||||
Basic Weighted Average Shares Outstanding | 97.24M | 101M | 103M | 105M | 106M | |||||
Net EPS - Diluted | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | |||||
Diluted EPS - Continuing Operations | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | |||||
Diluted Weighted Average Shares Outstanding | 97.24M | 109M | 103M | 105M | 106M | |||||
Normalized Basic EPS | -0.07 | 0.11 | -0.31 | -0.51 | -1.24 | |||||
Normalized Diluted EPS | -0.07 | 0.1 | -0.31 | -0.51 | -1.24 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.19M | 38.56M | -34.53M | -79.34M | -216M | |||||
EBITA | -587K | 30.81M | -43.69M | -88.91M | -226M | |||||
EBIT | -587K | 30.81M | -43.69M | -88.91M | -226M | |||||
EBITDAR | 10.8M | 44.51M | -27.18M | -72.24M | -208M | |||||
Effective Tax Rate - (Ratio) | 18.06 | -9.42 | -12.05 | -13.06 | -7.98 | |||||
Current Foreign Taxes | -1.74M | -1.71M | 6.28M | 10.69M | 15.3M | |||||
Total Current Taxes | -1.74M | -1.71M | 6.28M | 10.69M | 15.3M | |||||
Deferred Foreign Taxes | 144K | - | - | - | - | |||||
Total Deferred Taxes | 144K | - | - | - | - | |||||
Normalized Net Income | -6.77M | 10.75M | -32.34M | -53.79M | -132M | |||||
Interest on Long-Term Debt | 14.21M | 18.05M | 4.81M | 4.59M | 3.38M | |||||
Non-Cash Pension Expense | 52K | 105K | -421K | -621K | -320K | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 96.68M | 118M | 137M | 174M | 224M | |||||
General and Administrative Expenses | 87.95M | 107M | 126M | 133M | 163M | |||||
Research And Development Expense From Footnotes | 79M | 132M | 201M | 206M | 223M | |||||
Net Rental Expense, Total | 4.61M | 5.95M | 7.35M | 7.11M | 8.2M | |||||
Imputed Operating Lease Interest Expense | 3.22M | 2.74M | 394K | 325K | 366K | |||||
Imputed Operating Lease Depreciation | 1.39M | 3.21M | 6.95M | 6.78M | 7.83M | |||||
Stock-Based Comp., COGS (Total) | 2.23M | 2.22M | 3.47M | 4.69M | 6.59M | |||||
Stock-Based Comp., R&D Exp. (Total) | 7.57M | 18.12M | 27.6M | 30.79M | 31.83M | |||||
Stock-Based Comp., S&M Exp. (Total) | 11.9M | 17.67M | 22.67M | 28.83M | 35.97M | |||||
Stock-Based Comp., G&A Exp. (Total) | 30.72M | 37.7M | 41.16M | 42.65M | 41.23M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 52.42M | 75.72M | 94.9M | 107M | 116M |